Parametrica Management Ltd acquired a new stake in Integra LifeSciences Holdings Corp. (NASDAQ:IART) during the second quarter, Holdings Channel reports. The fund acquired 4,079 shares of the company’s stock, valued at approximately $325,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. First Manhattan Co. purchased a new stake in Integra LifeSciences Holdings Corp. during the second quarter valued at $135,000. BlackRock Inc. raised its stake in Integra LifeSciences Holdings Corp. by 137.2% in the first quarter. BlackRock Inc. now owns 2,016 shares of the company’s stock valued at $136,000 after buying an additional 1,166 shares during the period. Legal & General Group Plc raised its stake in Integra LifeSciences Holdings Corp. by 23.1% in the first quarter. Legal & General Group Plc now owns 6,278 shares of the company’s stock valued at $420,000 after buying an additional 1,179 shares during the period. Aperio Group LLC raised its stake in Integra LifeSciences Holdings Corp. by 21.8% in the first quarter. Aperio Group LLC now owns 7,780 shares of the company’s stock valued at $524,000 after buying an additional 1,392 shares during the period. Finally, Capstone Asset Management Co. raised its stake in Integra LifeSciences Holdings Corp. by 9.0% in the second quarter. Capstone Asset Management Co. now owns 10,530 shares of the company’s stock valued at $840,000 after buying an additional 870 shares during the period. Hedge funds and other institutional investors own 88.47% of the company’s stock.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) traded up 0.13% during trading on Friday, hitting $86.13. The stock had a trading volume of 335,482 shares. Integra LifeSciences Holdings Corp. has a 1-year low of $54.75 and a 1-year high of $88.86. The firm has a market cap of $3.22 billion, a price-to-earnings ratio of 355.91 and a beta of 0.52. The firm’s 50 day moving average is $84.88 and its 200 day moving average is $74.88.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) last posted its quarterly earnings data on Thursday, July 28th. The company reported $0.79 EPS for the quarter, topping the Zacks’ consensus estimate of $0.76 by $0.03. Integra LifeSciences Holdings Corp. had a return on equity of 15.41% and a net margin of 0.79%. The company had revenue of $249.30 million for the quarter, compared to the consensus estimate of $243.17 million. During the same quarter in the previous year, the business earned $0.79 EPS. The company’s quarterly revenue was up 17.2% compared to the same quarter last year. On average, analysts anticipate that Integra LifeSciences Holdings Corp. will post $3.48 earnings per share for the current year.

IART has been the topic of a number of analyst reports. Barclays PLC increased their price objective on Integra LifeSciences Holdings Corp. from $74.00 to $77.00 and gave the company an “equal weight” rating in a research note on Thursday, June 2nd. Jefferies Group increased their price objective on Integra LifeSciences Holdings Corp. from $81.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, July 29th. JPMorgan Chase & Co. initiated coverage on Integra LifeSciences Holdings Corp. in a research note on Wednesday, July 13th. They set an “overweight” rating on the stock. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $94.00 price objective (up previously from $86.00) on shares of Integra LifeSciences Holdings Corp. in a research note on Sunday, August 21st. Finally, Zacks Investment Research raised Integra LifeSciences Holdings Corp. from a “hold” rating to a “buy” rating and set a $85.00 price objective on the stock in a research note on Tuesday, June 28th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $82.88.

In other news, Director Raymond G. Murphy sold 2,600 shares of the business’s stock in a transaction on Tuesday, August 23rd. The stock was sold at an average price of $86.64, for a total transaction of $225,264.00. Following the sale, the director now directly owns 33,047 shares of the company’s stock, valued at $2,863,192.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Peter J. Arduini sold 24,009 shares of the business’s stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $84.52, for a total value of $2,029,240.68. Following the sale, the chief executive officer now directly owns 29,602 shares in the company, valued at $2,501,961.04. The disclosure for this sale can be found here. 22.00% of the stock is owned by insiders.

Integra LifeSciences Holdings Corp. Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties.

5 Day Chart for NASDAQ:IART

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corp. (NASDAQ:IART).

Receive News & Ratings for Integra LifeSciences Holdings Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.